HRP20161166T1 - Tapentadol za uporabu u liječenju sindroma iritabilnog crijeva - Google Patents
Tapentadol za uporabu u liječenju sindroma iritabilnog crijeva Download PDFInfo
- Publication number
- HRP20161166T1 HRP20161166T1 HRP20161166TT HRP20161166T HRP20161166T1 HR P20161166 T1 HRP20161166 T1 HR P20161166T1 HR P20161166T T HRP20161166T T HR P20161166TT HR P20161166 T HRP20161166 T HR P20161166T HR P20161166 T1 HRP20161166 T1 HR P20161166T1
- Authority
- HR
- Croatia
- Prior art keywords
- tapentadol
- bowel syndrome
- irritable bowel
- use according
- drug
- Prior art date
Links
- 208000002551 irritable bowel syndrome Diseases 0.000 title claims 11
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 title claims 10
- 229960005126 tapentadol Drugs 0.000 title claims 10
- 239000003814 drug Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 5
- 206010012735 Diarrhoea Diseases 0.000 claims 4
- 206010010774 Constipation Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (8)
1. Tapentadol naznačen time da je za uporabu u liječenju sindroma iritabilnog crijeva.
2. Tapentadol za uporabu prema zahtjevu 1, naznačen time da je sindrom iritabilnog crijeva odabran iz skupine koja sadrži sindrom iritabilnog crijeva s proljevom, sindrom iritabilnog crijeva s prevladavajućim proljevom, sindrom iritabilnog crijeva bez proljeva, sindrom iritabilnog crijeva s prevladavajućom konstipacijom, sindrom iritabilnog crijeva s naizmjeničnim uzorkom stolice (sindrom iritabilnog crijeva s naizmjeničnom konstipacijom i proljevom, mješoviti sindrom iritabilnog crijeva) i post infektivni sindrom iritabilnog crijeva.
3. Tapentadol za uporabu prema zahtjevu 1 ili 2, naznačen time da se nalazi u lijeku.
4. Tapentadol za uporabu prema zahtjevu 3, naznačen time da je lijek u krutom stanju.
5. Tapentadol za uporabu prema zahtjevu 3 ili 4, naznačen time da je lijek formuliran za oralnu primjenu.
6. Tapentadol za uporabu prema bilo kojem od zahtjeva 3-5, naznačen time da lijek je tableta.
7. Tapentadol za uporabu prema bilo kojem od zahtjeva 3-6, naznačen time da je lijek formuliran za primjenu dva puta dnevno (bid).
8. Tapentadol za uporabu prema bilo kojem od zahtjeva 3-7, naznačen time da lijek sadrži tapentadol u količini od 10 do 300 mg.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10006782 | 2010-06-30 | ||
| PCT/EP2011/003217 WO2012000666A1 (en) | 2010-06-30 | 2011-06-29 | Tapentadol for use in the treatment of irritable bowel syndrome |
| EP11733571.1A EP2588093B1 (en) | 2010-06-30 | 2011-06-29 | Tapentadol for use in the treatment of irritable bowel syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161166T1 true HRP20161166T1 (hr) | 2016-11-04 |
Family
ID=43037243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161166TT HRP20161166T1 (hr) | 2010-06-30 | 2016-09-12 | Tapentadol za uporabu u liječenju sindroma iritabilnog crijeva |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US20120004317A1 (hr) |
| EP (1) | EP2588093B1 (hr) |
| JP (1) | JP5856613B2 (hr) |
| AU (1) | AU2011273907B2 (hr) |
| BR (1) | BR112012033644A2 (hr) |
| CA (1) | CA2795923C (hr) |
| CY (1) | CY1117742T1 (hr) |
| DK (1) | DK2588093T3 (hr) |
| ES (1) | ES2591354T3 (hr) |
| HR (1) | HRP20161166T1 (hr) |
| HU (1) | HUE029952T2 (hr) |
| MX (1) | MX2012012509A (hr) |
| PL (1) | PL2588093T3 (hr) |
| PT (1) | PT2588093T (hr) |
| RS (1) | RS55009B1 (hr) |
| SI (1) | SI2588093T1 (hr) |
| WO (1) | WO2012000666A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3277274A4 (en) | 2015-04-01 | 2018-12-05 | Cedars-Sinai Medical Center | Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4426245A1 (de) | 1994-07-23 | 1996-02-22 | Gruenenthal Gmbh | 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung |
| PE20030527A1 (es) | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| US7759079B2 (en) * | 2004-05-13 | 2010-07-20 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| EP1985292A1 (en) * | 2007-04-23 | 2008-10-29 | Grünenthal GmbH | Titration of tapentadol |
| EP1997493A1 (en) * | 2007-05-28 | 2008-12-03 | Laboratorios del Dr. Esteve S.A. | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand |
| EP2014288A1 (en) * | 2007-07-10 | 2009-01-14 | Laboratorios del Dr. Esteve S.A. | Combination of benzyl-4, 5-dihydro-1H-imidazole derivative and an opioid receptor ligand |
| CA2705422A1 (en) * | 2007-11-16 | 2009-05-22 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating visceral pain |
| US7872046B2 (en) * | 2008-01-25 | 2011-01-18 | Xenoport, Inc. | Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use |
-
2011
- 2011-06-29 BR BR112012033644A patent/BR112012033644A2/pt not_active Application Discontinuation
- 2011-06-29 MX MX2012012509A patent/MX2012012509A/es active IP Right Grant
- 2011-06-29 JP JP2013517080A patent/JP5856613B2/ja active Active
- 2011-06-29 PL PL11733571T patent/PL2588093T3/pl unknown
- 2011-06-29 AU AU2011273907A patent/AU2011273907B2/en active Active
- 2011-06-29 US US13/172,103 patent/US20120004317A1/en not_active Abandoned
- 2011-06-29 SI SI201130953A patent/SI2588093T1/sl unknown
- 2011-06-29 HU HUE11733571A patent/HUE029952T2/en unknown
- 2011-06-29 WO PCT/EP2011/003217 patent/WO2012000666A1/en active Application Filing
- 2011-06-29 ES ES11733571.1T patent/ES2591354T3/es active Active
- 2011-06-29 DK DK11733571.1T patent/DK2588093T3/en active
- 2011-06-29 PT PT117335711T patent/PT2588093T/pt unknown
- 2011-06-29 RS RS20160677A patent/RS55009B1/sr unknown
- 2011-06-29 EP EP11733571.1A patent/EP2588093B1/en not_active Revoked
- 2011-06-29 CA CA2795923A patent/CA2795923C/en active Active
-
2012
- 2012-12-21 US US13/723,635 patent/US20130116334A1/en not_active Abandoned
-
2016
- 2016-07-06 CY CY20161100637T patent/CY1117742T1/el unknown
- 2016-09-12 HR HRP20161166TT patent/HRP20161166T1/hr unknown
- 2016-10-26 US US15/335,087 patent/US20170042836A1/en not_active Abandoned
-
2017
- 2017-04-13 US US15/486,543 patent/US20170216226A1/en not_active Abandoned
-
2018
- 2018-03-15 US US15/922,375 patent/US20180200205A1/en not_active Abandoned
-
2021
- 2021-03-29 US US17/215,050 patent/US20210212967A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011273907B2 (en) | 2015-03-19 |
| JP5856613B2 (ja) | 2016-02-10 |
| EP2588093B1 (en) | 2016-06-15 |
| US20170216226A1 (en) | 2017-08-03 |
| US20120004317A1 (en) | 2012-01-05 |
| DK2588093T3 (en) | 2016-08-29 |
| JP2013534926A (ja) | 2013-09-09 |
| US20170042836A1 (en) | 2017-02-16 |
| BR112012033644A2 (pt) | 2016-11-22 |
| US20210212967A1 (en) | 2021-07-15 |
| AU2011273907A1 (en) | 2013-02-14 |
| HUE029952T2 (en) | 2017-04-28 |
| PT2588093T (pt) | 2016-09-21 |
| WO2012000666A1 (en) | 2012-01-05 |
| US20130116334A1 (en) | 2013-05-09 |
| US20180200205A1 (en) | 2018-07-19 |
| CY1117742T1 (el) | 2017-05-17 |
| ES2591354T3 (es) | 2016-11-28 |
| EP2588093A1 (en) | 2013-05-08 |
| CA2795923C (en) | 2018-10-16 |
| CA2795923A1 (en) | 2012-01-05 |
| MX2012012509A (es) | 2012-12-05 |
| SI2588093T1 (sl) | 2016-10-28 |
| RS55009B1 (sr) | 2016-11-30 |
| PL2588093T3 (pl) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210239T1 (hr) | Tetrahidrobiopterin za liječenje stanja povezanih s povišenim razinama fenilalanina | |
| RS52922B (en) | PREPARATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS AND THEIR USES | |
| RS52831B (en) | THIN BUPRENORPHINE TILES FOR DRUG REPLACEMENT THERAPY | |
| NZ592673A (en) | Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease | |
| CL2013000677A1 (es) | Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn. | |
| EA201400172A1 (ru) | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства | |
| MX2011008171A (es) | Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma. | |
| CL2011002248A1 (es) | Composicion farmaceutica oral de liberacion inmediata que comprende oxicodona y naloxona en una proporcion 2:1 en peso; uso de la composicion farmaceutica para tratar dolor intercurrente en paciente que sufren de dolor. | |
| HRP20130203T1 (hr) | Postupak za lijeäśenje sindroma iritabilnog crijeva zbog prevladavajuä†eg zatvora | |
| JP2013231087A5 (hr) | ||
| JP2015038135A5 (hr) | ||
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| JP2018527305A5 (hr) | ||
| BRPI0513598A (pt) | formas de dosagem em comprimidos revestidos de liberação entérica | |
| HRP20170734T1 (hr) | Povećana biodostupnost lijeka u terapiji naltreksonom | |
| NO20084826L (no) | Ny administrasjonsform av racecadotril | |
| WO2011104652A3 (en) | Veterinary compositions | |
| HRP20190891T1 (hr) | Medicinski proizvod i tretman | |
| MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| TNSN08385A1 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
| BR112015019776A2 (pt) | comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos | |
| HRP20161166T1 (hr) | Tapentadol za uporabu u liječenju sindroma iritabilnog crijeva | |
| JP2013032308A5 (hr) | ||
| AR089273A1 (es) | Composiciones para el cuidado oral que incluyen peliculas que cambian de color |